Literature DB >> 20932700

Diffusion-weighted MR imaging in comparison to integrated [¹⁸F]-FDG PET/CT for N-staging in patients with lung cancer.

Sandra Pauls1, Stefan A Schmidt, Markus S Juchems, Oliver Klass, Markus Luster, Sven Norbert Reske, Hans-Juergen Brambs, Sebastian Feuerlein.   

Abstract

PURPOSE: The purpose of this study was to prospectively determine the diagnostic accuracy of diffusion-weighted imaging (DWI) using MRI in the staging of thoracic lymph nodes in patients with lung cancer, and to compare the performance to that of PET/CT. PATIENTS AND
METHOD: 20 consecutive patients (pts) with histologically proven lung cancer were included in this study. In all pts FDG-PET/CT was routinely performed to stage lung carcinoma. Additionally, MRI (1.5T) was performed including native T1w, T1w post contrast medium, T2w, and DWI sequences. Regarding the N stage based on the results of the PET/CT there were 5 patients with N0, 3 patients with N1, 5 patients with N2 and 7 patients with N3. Image analysis was performed by two radiologists (R1 and R2), respectively. The reviewers had to chose between 1 (at least one lymph node within a station is malignant) or 0 (no lymph nodes suspicious for malignancy). First the T1 post contrast sequence was analyzed. In a second step the DWI sequence (b=800) was analyzed. Both steps were performed in a blinded fashion.
RESULTS: MR imaging with or without DWI only agreed with the results of the PET/CT regarding the N stage in 80% of the patients-15% were understaged and 5% overstaged. There was excellent interobserver agreement; the N-staging result only differed in 1 patient for DWI, resulting in correlation coefficients of 0.98 for DWI and 1.0 for MRI. Compared to PET-CT MRI overstaged one and understaged 4 patients, while DWI overstaged one and understaged 3 patients. This resulted in correlation coefficients of 0.814 (R1 and R2) for MRI and 0.815 (R1) and 0.804 (R2) for DWI. Regarding the ADC values there were no significant differences between ipsilateral hilar (1.03 mm(2)/s ± 0.13), subcarinal (0.96 mm(2)/s±0.24), ipsilateral mediastinal (1.0mm(2)/s ± 0.18), contralateral mediastinal (0.93 mm(2)/s ± 0.23) and supraclavicular (0.9 mm(2)/s ± 0.23) lymph nodes.
CONCLUSION: Diffusion-weighted imaging does not show a clear advantage over conventional MR protocols in the N-staging of lung cancer. MRI with or without DWI shows a moderately correlation with PET/CT with a tendency for understaging.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20932700     DOI: 10.1016/j.ejrad.2010.09.001

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  20 in total

1.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

Review 2.  Magnetic resonance imaging in lung: a review of its potential for radiotherapy.

Authors:  Shivani Kumar; Gary Liney; Robba Rai; Lois Holloway; Daniel Moses; Shalini K Vinod
Journal:  Br J Radiol       Date:  2016-02-03       Impact factor: 3.039

3.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

4.  Usefulness of 3T diffusion-weighted MRI for discrimination of reactive and metastatic cervical lymph nodes in patients with oral squamous cell carcinoma: a pilot study.

Authors:  J Si; S Huang; H Shi; Z Liu; Q Hu; G Wang; G Shen; D Zhang
Journal:  Dentomaxillofac Radiol       Date:  2014-01-22       Impact factor: 2.419

Review 5.  Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review.

Authors:  Bruno Hochhegger; Matheus Zanon; Stephan Altmayer; Gabriel S Pacini; Fernanda Balbinot; Martina Z Francisco; Ruhana Dalla Costa; Guilherme Watte; Marcel Koenigkam Santos; Marcelo C Barros; Diana Penha; Klaus Irion; Edson Marchiori
Journal:  Lung       Date:  2018-10-09       Impact factor: 2.584

Review 6.  PET-MR imaging using a tri-modality PET/CT-MR system with a dedicated shuttle in clinical routine.

Authors:  Patrick Veit-Haibach; Felix Pierre Kuhn; Florian Wiesinger; Gaspar Delso; Gustav von Schulthess
Journal:  MAGMA       Date:  2012-10-09       Impact factor: 2.310

Review 7.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

8.  MRI of the lung (2/3). Why … when … how?

Authors:  J Biederer; M Beer; W Hirsch; J Wild; M Fabel; M Puderbach; E J R Van Beek
Journal:  Insights Imaging       Date:  2012-02-13

Review 9.  Diffusion magnetic resonance imaging of chest tumors.

Authors:  A A K Abdel Razek
Journal:  Cancer Imaging       Date:  2012-10-26       Impact factor: 3.909

Review 10.  PET/MR: a paradigm shift.

Authors:  Florian C Gaertner; Sebastian Fürst; Markus Schwaiger
Journal:  Cancer Imaging       Date:  2013-02-27       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.